For the first time, CMOS inverters and 6T-SRAM cells based on vertically stacked gate-all-around complementary FETs (CFETs) are experimentally demonstrated. Manufacturing difficulties of vertically ...

The urea can reduce the enzyme activity and stability by impairing the enzyme structure by direct interaction with the enzyme or by indirect action through changing the properties of surrounding ...

To make advances in using microbes to sustainably produce materials, it is necessary to find new molecular tools, or enzymes—but this is labor intensive. A Kobe University team has developed a ...

Enzyme-replacement therapy with recombinant human GAA (rhGAA) has been a standard treatment for Pompe's disease since it was approved in 2006, they noted.

Glutamate racemase (GR) catalyzes the cofactor independent stereoinversion of l- to d-glutamate for biosynthesis of bacterial cell walls. Because of its essential nature, this enzyme is under intense ...

The biotechnology company explained that Pombiliti is a recombinant human GAA enzyme naturally expressed with high levels of bis-M6P, designed for increased uptake into muscle cells, whereas ...

About Late-Onset Pompe Disease Late-onset Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to ...

Pombiliti is a recombinant human GAA enzyme designed for increased uptake into muscle cells, while Opfolda functions as an enzyme stabilizer in the blood. The approval was based on clinical data from ...

About Late-Onset Pompe Disease Late-onset Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA).

Both CRIM-positive and CRIM-negative patients with infantile-onset Pompe’s disease who were receiving enzyme-replacement therapy were reported to have anti-GAA IgG. 30-32 A negative immune ...